RxSight (RXST) Expected to Release Quarterly Earnings on Wednesday

RxSight (NASDAQ:RXST) will likely be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect RxSight to announce earnings of ($0.21) per share and revenue of $32.55 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

RxSight Stock Performance

RXST opened at $6.01 on Monday. RxSight has a 1-year low of $4.48 and a 1-year high of $13.22. The company has a market cap of $248.81 million, a price-to-earnings ratio of -5.32 and a beta of 1.13. The company’s fifty day moving average price is $5.26 and its two-hundred day moving average price is $6.75.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Weiss Ratings lowered RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of RxSight in a report on Tuesday, July 7th. Wells Fargo & Company reduced their target price on RxSight from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Thursday, May 7th. Wall Street Zen upgraded RxSight from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Finally, Jefferies Financial Group set a $6.50 price target on shares of RxSight in a research note on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $8.50.

Institutional Investors Weigh In On RxSight

A number of hedge funds have recently made changes to their positions in RXST. Millennium Management LLC increased its position in shares of RxSight by 130.6% in the third quarter. Millennium Management LLC now owns 2,193,062 shares of the company’s stock valued at $19,716,000 after acquiring an additional 1,241,885 shares during the period. Bank of America Corp DE increased its stake in shares of RxSight by 406.0% in the 3rd quarter. Bank of America Corp DE now owns 722,435 shares of the company’s stock worth $6,495,000 after acquiring an additional 579,653 shares in the last quarter. UBS Group AG lifted its holdings in shares of RxSight by 183.0% during the third quarter. UBS Group AG now owns 735,170 shares of the company’s stock valued at $6,609,000 after purchasing an additional 475,395 shares during the last quarter. Nuveen LLC boosted its holdings in RxSight by 609.7% in the fourth quarter. Nuveen LLC now owns 531,730 shares of the company’s stock worth $5,541,000 after acquiring an additional 456,803 shares in the last quarter. Finally, 4D Advisors LLC grew its position in RxSight by 343.9% during the 3rd quarter. 4D Advisors LLC now owns 554,930 shares of the company’s stock valued at $4,989,000 after purchasing an additional 429,930 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.